MedTrace Logo

Pulmonary Fibrosis Contact Registry

NCT01935726 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2019-03-13

No results posted yet for this study

Summary

As the name states, contact registries securely store contact information from groups of reasonably well-characterized patients (or primary supporters/caregivers) who are interested in being informed about ongoing or future research opportunities. Pulmonary fibrosis (PF) is a condition for which effective therapies have remained elusive, making drug trials and interventional research studies a mainstay in the PF arena over the last decade and for the foreseeable future. A PF Contact Registry will be a conduit to collect, analyze, and disseminate de-identified, group-level data on the clinical phenotypes of PF patients and will house contact information from patients who wish to be informed about research opportunities for which they may qualify. Data contained in the Registry will help inform research hypotheses and guide investigators as they develop research protocols by providing them with numbers of potential subjects who meet particular inclusion/exclusion criteria.

Conditions

  • Pulmonary Fibrosis of Any Cause
  • Primary Supporters/Caretakers of Patients With Pulmonary Fibrosis

Sponsors & Collaborators

  • Pulmonary Fibrosis Foundation

    collaborator OTHER

  • Patient-Centered Outcomes Research Institute

    collaborator OTHER

  • National Jewish Health

    lead OTHER

Principal Investigators

  • Jeff Swigris, DO, MS · National Jewish Health

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2019-03-10
Completion
2019-03-10

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01935726 on ClinicalTrials.gov